We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| HLS Therapeutics Inc | TSX:HLS | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.49% | 4.04 | 4.04 | 4.13 | 4.10 | 4.00 | 4.08 | 22,100 | 21:10:13 |
From Jan 2024 to Jan 2025
TORONTO, July 25, 2024 /CNW/ -Â HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 fiscal 2024 financial results on Thursday, August 8, 2024. The Company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be hosted by Mr. Craig Millian, Chief Executive Officer and Mr. John Hanna, Interim Chief Financial Officer. Slides to accompany management's prepared remarks will be available to view via the webcast.
CONFERENCE ID:Â 58793
DATE:Â Thursday, August 8, 2024
TIME:Â 8:30 a.m. ET
WEBCAST LINK:Â https://app.webinar.net/Bo1rqAKyNm9Â Â Â
TRADITIONAL DIAL-IN NUMBER: 1-800-836-8184 or 1-289-819-1350
RAPIDCONNECT:Â To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/3xE2Dl5Â Â Â
TAPED REPLAY:Â 1-888-660-6345 or 1-289-819-1450
REPLAY CODE: 58793#
The taped replay will be available for 14 days and the archived webcast will be available for 365 days.
A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.
Copyright 2024 Canada NewsWire
1 Year HLS Therapeutics Chart |
1 Month HLS Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
